Ifo-Cell

Ifosfamide, the active ingredient in Ifo-Cell, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of several adult solid tumours and lymphomas, including testicular, ovarian, soft‑tissue sarcoma, lung cancer and lymphoma.

GNH USA supplies Ifo-Cell as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution across EU and other regulated markets, adhering to stringent quality standards and providing cold‑chain logistics where required.

Ifosfamide is an alkylating antineoplastic agent used in the management of various malignant neoplasms. - Testicular cancer: achieves tumor reduction and potential cure in advanced disease. - Ovarian cancer: achieves cytoreduction and improves response to surgery. - Soft tissue sarcoma: achieves disease control and prolongs progression‑free survival. - Lung cancer: achieves tumor shrinkage in small‑cell or non‑small‑cell contexts. - Lymphoma: achieves remission in refractory cases.

Ifosfamide may be associated with a range of adverse reactions, varying from frequent, manageable events to rare but serious complications.

Common Side Effects: - Nausea and vomiting - Fatigue - Hemorrhagic cystitis - Myelosuppression (low blood counts)

Serious or Rare Side Effects: - Nephrotoxicity - Neurotoxicity (encephalopathy) - Secondary malignancies (e.g., therapy‑related leukemia) - Severe infection

When using Ifo-Cell, clinicians should observe several safety measures. - Monitor renal function: assess creatinine clearance before and during therapy. - Hydration and mesna prophylaxis: ensure adequate IV fluids and co‑administration of mesna to reduce bladder toxicity. - Hematologic monitoring: perform regular CBC to detect myelosuppression. - Pregnancy risk: contraindicated in pregnancy (Category D) and advise effective contraception. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ifosfamide interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Concomitant nephrotoxic agents (e.g., cisplatin) – increased renal injury. - Strong CYP3A4 inhibitors (e.g., ketoconazole) – elevated ifosfamide plasma levels. - Live vaccines – heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP inducers (e.g., rifampin) – reduced therapeutic effect. - Anticoagulants – enhanced bleeding risk from thrombocytopenia. - CNS depressants – may exacerbate neurotoxicity.